SKYE BIOSCIENCE INC (SKYE) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SKYE SKYE BIOSCIENCE INC

Watchlist

3.010
-0.240-7.38%

Close Dec 18 16:00 ET

91.32MMarket Cap5.68P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Give the Gift of Emotional Growth This Holiday Season
PR NewswireNov 21 08:39 ET
Insider Sale: Chief Development Officer of $SKYE (SKYE) Sells 19,489 Shares
Quiver QuantitativeNov 20 08:30 ET
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
GlobeNewswireNov 18 07:00 ET
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating
Moomoo NewsNov 14 09:31 ET · Ratings
Express News | Skye Bioscience Inc - Expects Interim Data for Cbeyond Phase 2 Trial in Q2 2025
ReutersNov 14 07:02 ET
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
GlobeNewswireNov 14 07:00 ET

Comments

Trytosaveabit

Nov 14 06:02

Update

$SKYE BIOSCIENCE INC (SKYE.US)$ Reuters· 1 min ago
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Jaguar8

Sep 23 06:03

NEWS

$SKYE BIOSCIENCE INC (SKYE.US)$
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience (Nasdaq: SKYE) has commented on Novo Nordisk's Phase 2a top-line data for monlunabant, a small-molecule oral CB1 inverse agonist. The study met its primary endpoint, showing at least 6% placebo-adjusted weight loss at 16 weeks. However, dose-dependent neuropsychiatric side effects were observed.
Skye highlights the advan...

Jaguar8

Aug 22 06:03

NEWS

$SKYE BIOSCIENCE INC (SKYE.US)$
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity. Skye Bioscience (Nasdaq: SKYE) has launched a Phase 2 clinical trial, CBeyond™, to evaluate its peripheral CB1 inhibitor, nimacimab, for weight loss in patients with obesity.
The study will assess nimacimab's efficacy as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Key aspects of the trial include:
- 12...

Skinny bulldog

May 20 07:43

$Scorpius Holdings (SCPX.US)$ Look at their peers. This is really undervalued. Once in a lifetime opporturnity.
$SKYE BIOSCIENCE INC (SKYE.US)$ $Boundless Bio (BOLD.US)$

MooMamaLlama

Sep 12, 2023 15:29

wow

$SKYE BIOSCIENCE INC (SKYE.US)$
this just shows it pays to follow up on things..
I had been eyeing this off for a while. Tried to buy in Jan at 0.019-0.020 but then left it alone as for whatever reason I wasn't able to buy.
Now I see it's gone from 0.02000 to a whopping 3.15.
Damn you Mr Market, that's ice cold!

MooMamaLlama: Not supported?

#Moo Army

Heat List

Overall

No Data